Evaluation of two anti-SARS-CoV-2 antibody immunoassays for monitoring patients on pre-exposure prophylaxis

• Published in: Diagnostic microbiology and infectious disease 2023-12, Vol.107 (4), p.116071-116071, Article 116071
• Main Authors: Vellas, Camille, Dimeglio, Chloé, Joncour, Emma, Staes, Laetitia, Jamme, Thibaut, Miedougé, Marcel, Da-Silva, Isabelle, Porcheron, Marion, Migueres, Marion, Kamar, Nassim, Izopet, Jacques
• Format: Article
• Language: English
• Subjects: Binding antibodies; Immunoassays; Neutralizing antibodies; PrEP; SARS-CoV-2
• ISSN: 0732-8893; 1879-0070
• DOI: 10.1016/j.diagmicrobio.2023.116071

Pre-exposure prophylaxis (PrEP) is crucial to prevent severe COVID-19 in immunocompromised patients. A reliable method is needed to quantify anti-SARS-CoV-2 antibody levels for personalized monitoring during PrEP. We measured the binding antibody concentrations of 63 immunocompromised patients receiving 300mg or 600mg tixagevimab/cilgavimab on PrEP day and twice during the following 3 months. All blood samples were tested using the Abbott anti-SARS-CoV-2 IgG II Quant assay, the Roche Elecsys anti-SARS-CoV-2 S assay, and live virus-based neutralization assays. The results of the two immunoassays were correlated on day 0, 1 month, and 3 months post-PrEP. Passing-Bablok regression demonstrated higher anti-S concentration values measured with the Roche immunoassay compared to those measured with the Abbott immunoassay. Antibody concentrations were higher after 600 mg tixagevimab/cilgavimab prophylaxis than after 300 mg. The neutralizing antibody titers obtained using the omicron BA.5 and BA.2.75 strains were low. Both automated immunoassays are suitable for monitoring immunocompromised patients on PrEP.